Spots Global Cancer Trial Database for response rate
Every month we try and update this database with for response rate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment | NCT00839111 | Colorectal Neop... | sorafenib FOLFIRI | 18 Years - 75 Years | Fudan University | |
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) | NCT04716075 | Chronic Lymphoc... Chronic Graft-v... Mantle Cell Lym... Adverse Event Response Rate | Acalabrutinib 2... | 18 Years - 80 Years | Polish Lymphoma Research Group | |
| The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients | NCT03019315 | Ovarian Cancer | 18 Years - | National Taiwan University Hospital | ||
| Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient | NCT00826644 | Carcinoma, Smal... | Belotecan Etoposide Cisplatin | 19 Years - 80 Years | Chonnam National University Hospital | |
| Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer | NCT00970138 | Gastric Carcino... | apatinib tablet | 18 Years - 70 Years | Fudan University | |
| The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients | NCT03019315 | Ovarian Cancer | 18 Years - | National Taiwan University Hospital | ||
| UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib | NCT02140840 | Multiple Myelom... | Trametinib | 18 Years - | University of Arkansas | |
| Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer | NCT00568529 | Gastric Cancer | Capecitabine an... | 18 Years - 70 Years | Fudan University | |
| Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient | NCT00826644 | Carcinoma, Smal... | Belotecan Etoposide Cisplatin | 19 Years - 80 Years | Chonnam National University Hospital | |
| UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib | NCT02140840 | Multiple Myelom... | Trametinib | 18 Years - | University of Arkansas | |
| Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer | NCT00595985 | Gastric Cancer | sorafenib | 18 Years - 70 Years | Fudan University | |
| Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome) | NCT00704704 | Myelodysplastic... | 5-aza-cytidine ... | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia | NCT01794702 | Leukemia | Decitabine Idarubicin Cytarabine Clofarabine | 18 Years - 64 Years | M.D. Anderson Cancer Center | |
| BAY43-9006 Phase II Study for Renal Cell Carcinoma | NCT00661375 | Carcinoma, Rena... | Nexavar (Sorafe... | 18 Years - | Bayer | |
| Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer | NCT00970138 | Gastric Carcino... | apatinib tablet | 18 Years - 70 Years | Fudan University | |
| Boron Neutron Capture Therapy (BNCT) for Locally Recurrent Head and Neck Cancer | NCT01173172 | Head and Neck C... | Boron Neutron C... | 18 Years - 80 Years | Taipei Veterans General Hospital, Taiwan | |
| Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome) | NCT00704704 | Myelodysplastic... | 5-aza-cytidine ... | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC | NCT00767377 | Gastric Cancer | EOF5 | 18 Years - 75 Years | Fudan University | |
| Preoperative Treatment of Patients With High Risk Thymoma | NCT00387868 | Thymoma | cisplatin and e... Surgical Resect... Concurrent Radi... | 18 Years - | Valley Health System | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination | NCT02578121 | Multiple Myelom... | Ixazomib Pomalidomide Dexamethasone | 18 Years - | University of Arkansas | |
| A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients | NCT00561743 | Multiple Myelom... | Bortezomib + pe... | 18 Years - 70 Years | Janssen-Ortho Inc., Canada | |
| Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer | NCT00568529 | Gastric Cancer | Capecitabine an... | 18 Years - 70 Years | Fudan University | |
| Study of Cetuximab to Treat Gastric Cancer | NCT00699881 | Gastric Cancer | cetuximab | 18 Years - 70 Years | Fudan University | |
| A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients | NCT00561743 | Multiple Myelom... | Bortezomib + pe... | 18 Years - 70 Years | Janssen-Ortho Inc., Canada | |
| Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia | NCT06034561 | Acute Lymphobla... Acute Lymphobla... | Bortezomib | 16 Years - 60 Years | Instituto do Cancer do Estado de São Paulo | |
| Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient | NCT00826644 | Carcinoma, Smal... | Belotecan Etoposide Cisplatin | 19 Years - 80 Years | Chonnam National University Hospital | |
| Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer | NCT01255137 | Adrenal Cortex ... | Axitinib | 18 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma | NCT00109005 | Melanoma | Revlimid | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec | NCT01116271 | Colorectal Canc... | AZD6244 Irinotecan | 18 Years - | AstraZeneca | |
| A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT00474188 | Diffuse Large B... | CC-5013 (lenali... dexamethasone | 18 Years - | Celgene | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer | NCT00970138 | Gastric Carcino... | apatinib tablet | 18 Years - 70 Years | Fudan University | |
| Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer | NCT00385996 | Carcinoma, Non-... | Tarceva (Erloti... | 18 Years - 85 Years | Weill Medical College of Cornell University | |
| Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma | NCT03503630 | Locally Advance... | COMPOUND 205526... Radiation Thera... mFOLFOX Total Mesorecta... | 18 Years - | American University of Beirut Medical Center | |
| Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer | NCT00595972 | Gastric Cancer | ECF-endostar | 18 Years - 70 Years | Fudan University | |
| Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment | NCT00839111 | Colorectal Neop... | sorafenib FOLFIRI | 18 Years - 75 Years | Fudan University | |
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) | NCT04716075 | Chronic Lymphoc... Chronic Graft-v... Mantle Cell Lym... Adverse Event Response Rate | Acalabrutinib 2... | 18 Years - 80 Years | Polish Lymphoma Research Group | |
| Study of Cetuximab to Treat Gastric Cancer | NCT00699881 | Gastric Cancer | cetuximab | 18 Years - 70 Years | Fudan University | |
| Study of Cetuximab to Treat Gastric Cancer | NCT00699881 | Gastric Cancer | cetuximab | 18 Years - 70 Years | Fudan University | |
| Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma | NCT03503630 | Locally Advance... | COMPOUND 205526... Radiation Thera... mFOLFOX Total Mesorecta... | 18 Years - | American University of Beirut Medical Center | |
| Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome) | NCT00704704 | Myelodysplastic... | 5-aza-cytidine ... | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer | NCT00385996 | Carcinoma, Non-... | Tarceva (Erloti... | 18 Years - 85 Years | Weill Medical College of Cornell University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
